Evidence map›Paper›PMID 30741721›Full record

ArticleThe Journal of clinical investigation2019

PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease.

Yajuan Li, Qingsong Hu, Chunlai Li, Ke Liang, Yu Xiang, Heidi Hsiao, Tina K Nguyen, Peter K Park, Sergey D Egranov, Chandrashekar R Ambati and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Post‑translational modifications in diabetic kidney disease (Review).International journal of molecular medicine · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Targeted Delivery of Triptolide Alleviates Diabetic Nephropathy via Inactivation of JAK2-STAT1 Signaling.Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Yajuan LiDepartment of Molecular and Cellular Oncology, and.
Qingsong HuDepartment of Molecular and Cellular Oncology, and.
Chunlai LiDepartment of Molecular and Cellular Oncology, and.
Ke LiangDepartment of Molecular and Cellular Oncology, and.
Yu XiangDepartment of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA.
Heidi HsiaoDepartment of Molecular and Cellular Oncology, and.
Tina K NguyenDepartment of Molecular and Cellular Oncology, and.
Peter K ParkDepartment of Molecular and Cellular Oncology, and.
Sergey D EgranovDepartment of Molecular and Cellular Oncology, and.
Chandrashekar R AmbatiAdvanced Technology Core, and.
Nagireddy PutluriDepartment of Molecular & Cell Biology, Baylor College of Medicine, Houston, Texas, USA.
David H HawkeDepartment of Systems Biology, and.
Leng HanDepartment of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA.
Mien-Chie HungDepartment of Molecular and Cellular Oncology, and.
Farhad R DaneshDivision of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Liuqing YangDepartment of Molecular and Cellular Oncology, and.
Chunru LinDepartment of Molecular and Cellular Oncology, and.
The Graduate Center, CUNY · USThe University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USCenter for Systems Biology · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
MicroRNA In Diabetic NephropathyR01DK091310 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANESH, FARHAD R · 2011 to 2024
$5.3M
Long Noncoding RNA Advocates Immune Resistant MicroenvironmentR01CA231011 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2019 to 2023
$2.9M
Identify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of SmokersR01CA216426 · NCI · BAYLOR COLLEGE OF MEDICINE · PI EL-ZEIN, RANDA A, PUTLURI, NAGIREDDY · 2018 to 2022
$2.0M
METABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCERU01CA167234 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PALAPATTU, GANESH S, SREEKUMAR, ARUN · 2012 to 2016
$1.9M
Combinatorial Treatment Strategies to Counteract EGFR ResistanceR01CA218036 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, LIUQING · 2017 to 2021
$1.8M
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder CancerR01CA220297 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PUTLURI, NAGIREDDY · 2017 to 2021
$1.8M
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast CancerR01CA218025 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2017 to 2020
$1.5M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
Nuclear Architecture, NcRNAs and Epigenetics in Transcriptional Regulation by ERR00DK094981 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2013 to 2015
$747k
Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate CancerR00CA166527 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, LIUQING · 2013 to 2015
$684k
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS R00 CA166527NCI NIH HHS R01 CA216426NCI NIH HHS R01 CA218025NCI NIH HHS R01 CA218036NCI NIH HHS R01 CA220297NCI NIH HHS R01 CA231011NCI NIH HHS U01 CA167234NIDDK NIH HHS R00 DK094981NIDDK NIH HHS R01 DK091310NIH HHS S10 OD012304
6 · The paper itself

Abstract

Epithelial-mesenchymal transition (EMT) contributes significantly to interstitial matrix deposition in diabetic kidney disease (DKD). However, detection of EMT in kidney tissue is impracticable, and anti-EMT therapies have long been hindered. We reported that phosphatase and tensin homolog (PTEN) promoted transforming growth factor beta 1 (TGF-β), sonic hedgehog (SHH), connective tissue growth factor (CTGF), interleukin 6 (IL-6), and hyperglycemia-induced EMT when PTEN was modified by a MEX3C-catalyzed K27-linked polyubiquitination at lysine 80 (referred to as PTENK27-polyUb). Genetic inhibition of PTENK27-polyUb alleviated Col4a3 knockout-, folic acid-, and streptozotocin-induced (STZ-induced) kidney injury. Serum and urine PTENK27-polyUb concentrations were negatively correlated with glomerular filtration rate (GFR) for diabetic patients. Mechanistically, PTENK27-polyUb facilitated dephosphorylation and protein stabilization of TWIST, SNAI1, and YAP in renal epithelial cells, leading to enhanced EMT. We identified that a small molecule, triptolide, inhibited MEX3C-catalyzed PTENK27-polyUb and EMT of renal epithelial cells. Treatment with triptolide reduced TWIST, SNAI1, and YAP concurrently and improved kidney health in Col4a3 knockout-, folic acid-injured disease models and STZ-induced, BTBR ob/ob diabetic nephropathy models. Hence, we demonstrated the important role of PTENK27-polyUb in DKD and a promising therapeutic strategy that inhibited the progression of DKD.

Indexed as

Epithelial-Mesenchymal TransitionAdaptor Proteins, Signal TransducingAnimalsAutoantigensCell Cycle ProteinsCell LineCollagen Type IVDiabetes Mellitus, ExperimentalDiabetic NephropathiesHumansKidneyMiceMice, KnockoutPTEN PhosphohydrolaseSnail Family Transcription FactorsTwist-Related Protein 1Adaptor Proteins, Signal TransducingAutoantigensCell Cycle ProteinsCollagen Type IVPTEN PhosphohydrolasePten protein, mouseSnai1 protein, mouseSnail Family Transcription FactorsTwist-Related Protein 1type IV collagen alpha3 chainYap1 protein, mouseYAP-Signaling ProteinsCell BiologyChronic kidney diseaseDiabetesNephrologyProteases

Identifiers

PMID30741721
PMCPMC6391108
OpenAlexW2912486502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.